8-K: InspireMD Reports Record Q4 Revenue, Advances Clinical Trials

InspireMD announced record fourth-quarter revenue for its CGuard EPS product, alongside positive clinical trial updates and strategic partnerships.

Summary

• InspireMD reported a record fourth-quarter revenue of $1.76 million for its CGuard EPS product, marking a 71.6% increase compared to the same period in 2022.
• The company sold 3,107 CGuard EPS stent systems in Q4 2023, a 74.5% increase year-over-year.
• Positive 30-day results from the C-GUARDIANS U.S. clinical trial were presented, showing a low major adverse event rate of 0.95% for patients treated with CGuard EPS.
• InspireMD received re-certification of its CE Mark under the European Union's new Medical Device Regulation (MDR).
• The company appointed lead principal investigators for the C-GUARDIANS II clinical trial and an advisor to the company.
• A strategic agreement was formed with the Jacobs Institute to study CGuard EPS for acute ischemic stroke.
• Total revenue for the full year 2023 was $6.205 million, a 20% increase from $5.171 million in 2022.
• Gross profit for the full year 2023 increased by 61.8% to $1.807 million.
• The net loss for the full year 2023 was $19.916 million, or $0.82 per share, compared to a net loss of $18.491 million, or $2.35 per share, in 2022.
• Cash, cash equivalents, short-term bank deposits, and marketable securities totaled $39.0 million as of December 31, 2023, compared to $17.8 million at the end of 2022.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative information. The strong revenue growth, positive clinical trial results, and increased cash position are very positive. However, the ongoing net losses and the need for potential future capital raises temper the overall sentiment.

Positives

• The company achieved record revenue for its CGuard EPS product in the fourth quarter of 2023.
• Sales of CGuard EPS stent systems saw a significant increase in the fourth quarter of 2023.
• The C-GUARDIANS clinical trial demonstrated a low major adverse event rate, indicating the safety and efficacy of the CGuard EPS.
• The CE Mark re-certification allows InspireMD to leverage new product development pathways.
• The company has a strong cash position of $39.0 million.
• Gross profit and gross margin increased significantly for both the quarter and the full year.

Negatives

• The company reported a net loss of $5.405 million for the fourth quarter of 2023.
• The net loss for the full year 2023 was $19.916 million.
• Operating expenses increased by 23% in the fourth quarter and 15.7% for the full year.

Risks

• The company has a history of recurring losses and negative cash flows.
• There is uncertainty regarding the adequacy of the company's liquidity to pursue its business objectives.
• The company may need to raise additional capital, which could be costly or difficult to obtain.
• There are risks associated with market acceptance of the company's products.
• The company faces intense competition in the medical device industry.
• The company is dependent on a single manufacturing facility.
• There are risks associated with conducting business in multiple foreign jurisdictions.

Future Outlook

The company expects to report 12-month follow-up data from the C-GUARDIANS trial mid-year, followed by a Premarket Approval (PMA) application submission. They also plan to advance their new product pipeline, including the C-GUARDIANS II clinical trial and the early feasibility study with the Jacobs Institute.

Management Comments

• We delivered another strong quarter of sales growth in our approved CE Mark territories while at the same time advancing our U.S. clinical trial and product development pipeline.
• Our total revenue of $1.76 million represents a record quarter and an increase of nearly 72% over the comparable period in 2022.
• The data showed that stenting with CGuard in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95% from procedure through 30 days, which compares favorably to both surgery and alternative stenting options and represents best in class results to date of any pivotal trial of carotid intervention.
• We believe InspireMD is uniquely positioned with a best-in-class implant and solutions to support both CAS and TCAR procedures, with line-of-sight to significant clinical and regulatory catalysts this year and next.

Industry Context

The announcement comes as the medical device industry sees increasing focus on minimally invasive procedures for treating vascular diseases. The positive clinical trial results and regulatory approvals position InspireMD to compete effectively in the carotid stenting market, especially with the expanded CMS coverage for CAS.

Comparison to Industry Standards

• The reported 0.95% DSMI rate in the C-GUARDIANS trial compares favorably to historical rates for carotid endarterectomy (CEA), which typically range from 2% to 5% depending on patient risk factors.
• The results also compare well against other carotid stenting trials, where major adverse event rates can vary but are often higher than 1%.
• Companies like Abbott and Medtronic also offer carotid stenting solutions, but InspireMD's CGuard EPS is differentiated by its MicroNet technology and the reported low adverse event rate in the C-GUARDIANS trial.
• The 71.6% increase in Q4 revenue and 74.5% increase in stent sales indicate strong market adoption in CE Mark territories, suggesting a competitive advantage in those regions.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the positive revenue growth and clinical trial results, but also by the ongoing net losses and potential future capital raises.
• Employees may benefit from the company's growth and expansion.
• Customers (physicians and hospitals) will have access to a potentially improved carotid stenting solution.
• Suppliers may see increased demand for their products and services.
• Creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will report 12-month follow-up data from the C-GUARDIANS clinical trial mid-year.
• They plan to submit a Premarket Approval (PMA) application following the 12-month data.
• The C-GUARDIANS II clinical trial of SwitchGuard NPS will commence.
• The early feasibility study with the Jacobs Institute will be conducted.

Key Dates

Keywords

CGuard EPS, Carotid Artery Disease, Stent, Clinical Trial, CE Mark, Medical Device, Stroke Prevention, Revenue, Financial Results, InspireMD